Efficacy and Safety of Everolimus in de Novo Heart Transplant Recipients

NCT00150046 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

176

Enrollment

INDUSTRY

Sponsor class

Conditions

Heart Transplantation

Interventions

DRUG: Everolimus

Sponsor

Novartis Pharmaceuticals